USE TO TREATMENT OF:
Cachexia, Inoperable endometrial carcinoma, Metastatic endometrial carcinoma, Recurrent endometrial carcinoma, Inoperable carcinoma of the breast, Metastatic carcinoma, Recurrent carcinoma, unexplained weight loss, Anorexia, Cachexia, etc.
*The following content is generated by AI and is for reference only.
Megestrol Acetate is a synthetic progestin derivative widely utilized in clinical medicine for its potent hormonal activity. With the Chemical Abstracts Service (CAS) registry number 595-33-5, this compound features the molecular formula C24H30O4 and a molecular weight of approximately 386.49 g/mol. Structurally, it mimics the natural hormone progesterone but possesses enhanced oral bioavailability and metabolic stability, allowing for effective therapeutic outcomes with standard dosing regimens.
The primary medical applications of Megestrol Acetate focus on two distinct areas: oncology and appetite stimulation. In oncology, it serves as a critical treatment option for advanced metastatic breast cancer and endometrial carcinoma. By interfering with estrogen production and receptor binding, it helps inhibit tumor growth in hormone-sensitive cancers. Additionally, it is frequently prescribed off-label or as an approved therapy to manage severe cachexia and significant unintentional weight loss associated with chronic diseases such as AIDS and certain malignancies. Its ability to stimulate appetite and promote fat deposition makes it invaluable for improving the quality of life in palliative care settings.
Pharmacologically, Megestrol Acetate acts by binding to progesterone receptors, which triggers a cascade of effects including the suppression of gonadotropin secretion and modulation of the hypothalamic-pituitary-adrenal axis. While generally well-tolerated, patients must be monitored for potential side effects, including thromboembolic events, fluid retention, adrenal suppression, and hyperglycemia. Due to its impact on glucose metabolism, diabetic patients require careful management during treatment. The drug is typically administered orally in tablet form, with dosages varying significantly based on the specific indication and individual patient response.
In summary, Megestrol Acetate remains a cornerstone in the management of hormone-dependent cancers and wasting syndromes. Its unique pharmacological profile offers clinicians a versatile tool to address both disease progression and symptom management. Continued research ensures its optimal integration into treatment protocols, balancing efficacy with safety considerations for diverse patient populations requiring long-term hormonal therapy.